Ubiquitin-specific protease 7-mediated stabilization of discoidin domain receptor 1 drives progression of TP53-Mutant cancers
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110515 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Yiying Xue und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, Shanghai Key Laboratory of Signaling and Disease Research,…. Hauptthemen laut MEDLINE: Ubiquitin-Specific Peptidase 7, Tumor Suppressor Protein p53, Discoidin Domain Receptor 1, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, National Key Research and Development Program of China.
Abstract (Originalsprache)
Receptor tyrosine kinase DDR1 (Discoidin Domain Receptor 1) interacts with the extracellular matrix (ECM) to promote tumor cell proliferation through its intracellular kinase activity, while its extracellular non-enzymatic domain creates a physical barrier for immune evasion. Although DDR1 inhibitors and antibodies have been developed, targeting DDR1 kinase activity alone cannot fully block the biological effects mediated by its scaffold function. Therefore, developing DDR1 degraders presents a potentially more effective therapeutic strategy. Through screening a proprietary small-molecule ubiquitination library, we identified NSC632839, which significantly induces DDR1 protein degradation. Mechanistically, chemical proteomics and genetic studies demonstrated that NSC632839 functions by inhibiting USP7, which interacts with, stabilizes, and deubiquitinates DDR1, preventing its proteasomal degradation. Importantly, we observed that TP53 loss or mutation in tumor cells and clinical samples markedly upregulates DDR1 expression, thereby enhancing its interaction with USP7. Inhibition of USP7 with NSC632839 or other selective inhibitors restores TP53 expression, resulting in a significant reduction in DDR1 levels. In various preclinical models, targeting USP7 with NSC632839 effectively eliminates tumor cells, offering a promising therapeutic strategy to overcome tumor relapse driven by TP53 mutations, both in vitro and in vivo. This study highlights the potential of DDR1 degradation via USP7 inhibition as a novel approach to treat TP53 mutation-enriched tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai,…
- Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
- Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of General Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China. Electronic address: bingbinglian3@163.com.
- Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address: yuzeng2013@163.com.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- National Key Research and Development Program of China
- Dana-Farber Cancer Institute
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- School of Medicine, Shanghai Jiao Tong University
- Harvard Medical School
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Xue, Y., Xiu, B., Yang, M., Zhang, Y., Yang, C., Zhang, L., Yan, Y., Luo, X., Huang, Y., Mei, H., Li, G., Zhou, L., Chen, Y., Zhang, W., Qian, C., Zhang, P., Liu, J., Liang, A., Zeng, Y., & Yang, J. (2025). Ubiquitin-specific protease 7-mediated stabilization of discoidin domain receptor 1 drives progression of TP53-Mutant cancers. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110515
Vancouver
Xue Y, Xiu B, Yang M, Zhang Y, Yang C, Zhang L, et al. Ubiquitin-specific protease 7-mediated stabilization of discoidin domain receptor 1 drives progression of TP53-Mutant cancers. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110515
BibTeX
@article{Xue2025,
author = {Xue, Yiying and Xiu, Bing and Yang, Muye and Zhang, Yanwei and Yang, Changpeng and Zhang, Lele and Yan, Yilv and Luo, Xiu and Huang, Yushan and Mei, Husheng and Li, Guiming and Zhou, Lixin and Chen, Yisa and Zhang, Wenjun and Qian, Changlin and Zhang, Peng and Liu, Juan and Liang, Aibin and Zeng, Yu and Yang, Jing},
title = {Ubiquitin-specific protease 7-mediated stabilization of discoidin domain receptor 1 drives progression of TP53-Mutant cancers},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110515}
}
EUVIMED